• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Attainment of Inactive Disease Following Discontinuation of Adalimumab Monotherapy in Patients With Enthesitis-Related Arthritis: A Real-Life, Dual-Center Experience.

作者信息

Papailiou Stayroula, Dasoula Foteini, Tsolia Maria N, Maritsi Despoina N

机构信息

From the Infectious Diseases, Immunology and Rheumatology Unit, Second Department of Paediatrics, "P. & A. Kyriakou" Children's Hospital, National and Kapodistrian University of Athens, Athens, Greece.

出版信息

J Clin Rheumatol. 2022 Mar 1;28(2):e616-e618. doi: 10.1097/RHU.0000000000001762.

DOI:10.1097/RHU.0000000000001762
PMID:34145201
Abstract
摘要

相似文献

1
Attainment of Inactive Disease Following Discontinuation of Adalimumab Monotherapy in Patients With Enthesitis-Related Arthritis: A Real-Life, Dual-Center Experience.停用阿达木单抗单药治疗后，附着点炎相关关节炎患者达到疾病非活动状态：一项真实世界、双中心经验。
J Clin Rheumatol. 2022 Mar 1;28(2):e616-e618. doi: 10.1097/RHU.0000000000001762.
2
Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry.阿达木单抗对比阿达木单抗联合甲氨蝶呤治疗幼年特发性关节炎：来自德国BIKER注册研究的长期数据。
Scand J Rheumatol. 2019 Mar;48(2):95-104. doi: 10.1080/03009742.2018.1488182. Epub 2018 Nov 9.
3
Comparative Effectiveness of Tumor Necrosis Factor Agents and Disease-modifying Antirheumatic Therapy in Children with Enthesitis-related Arthritis: The First Year after Diagnosis.肿瘤坏死因子制剂与疾病修饰抗风湿疗法在附着点相关关节炎儿童中的比较疗效：诊断后第一年。
J Rheumatol. 2018 Jan;45(1):107-114. doi: 10.3899/jrheum.170251. Epub 2017 Sep 15.
4
Adalimumab or etanercept as first line biologic therapy in enthesitis related arthritis (ERA) - a drug-survival single centre study spanning 10 years.阿达木单抗或依那西普作为附着点炎相关关节炎（ERA）的一线生物治疗——一项为期10年的单中心药物生存研究。
Semin Arthritis Rheum. 2022 Aug;55:152038. doi: 10.1016/j.semarthrit.2022.152038. Epub 2022 May 28.
5
A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis.一项关于阿达木单抗治疗与附着点炎相关关节炎儿科患者的随机、双盲、安慰剂对照多中心研究。
Arthritis Care Res (Hoboken). 2015 Nov;67(11):1503-12. doi: 10.1002/acr.22657.
6
Lichen nitidus in a child receiving adalimumab for juvenile idiopathic arthritis.一名接受阿达木单抗治疗幼年特发性关节炎的儿童出现光泽苔藓。
Indian J Dermatol Venereol Leprol. 2021 May-Jun;87(3):408-409. doi: 10.25259/IJDVL_241_19.
7
Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.一线抗TNF药物在成人和青少年发病的炎症性关节炎患者中的真实世界10年保留率：异同点
Clin Rheumatol. 2017 Aug;36(8):1747-1755. doi: 10.1007/s10067-017-3712-8. Epub 2017 Jun 8.
8
Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate.多关节型幼年特发性关节炎患者接受阿达木单抗联合或不联合甲氨蝶呤治疗的长期结局。
RMD Open. 2020 Jul;6(2). doi: 10.1136/rmdopen-2020-001208.
9
Attainment of inactive disease status following initiation of TNF-α inhibitor therapy for juvenile idiopathic arthritis: enthesitis-related arthritis predicts persistent active disease.接受 TNF-α 抑制剂治疗的幼年特发性关节炎达到无病活动状态：附着点关节炎预示持续的活动性疾病。
J Rheumatol. 2011 Dec;38(12):2675-81. doi: 10.3899/jrheum.110427. Epub 2011 Nov 15.
10
Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis.依那西普和阿达木单抗在2至4岁幼年特发性关节炎儿童中的安全性和有效性。
Clin Rheumatol. 2016 Dec;35(12):2925-2931. doi: 10.1007/s10067-016-3439-y. Epub 2016 Oct 5.

引用本文的文献

1
Approaches and outcomes of adalimumab discontinuation in patients with well-controlled inflammatory arthritis: a systematic search and review.病情得到良好控制的炎性关节炎患者停用阿达木单抗的方法及结果：一项系统检索与综述
Pediatr Rheumatol Online J. 2024 Dec 30;22(1):112. doi: 10.1186/s12969-024-01046-3.
2
Biomarkers of Response to Biologic Therapy in Juvenile Idiopathic Arthritis.幼年特发性关节炎生物治疗反应的生物标志物
Front Pharmacol. 2021 Feb 2;11:635823. doi: 10.3389/fphar.2020.635823. eCollection 2020.